Target intelligence / Profile preview

Human immunodeficiency virus type 1 glycoprotein 41 N-terminal heptad repeat trimer pocket (gp41 N-trimer pocket)

Target
gp41 N-trimer pocket
Molecular classification
Viral fusion protein, Envelope glycoprotein, Type I transmembrane protein subunit
01

Overview

The HIV-1 gp41 N-trimer pocket is a highly conserved hydrophobic cavity located at the base of the N-terminal heptad repeat (NHR) coiled-coil trimer of the gp41 transmembrane glycoprotein (Chan et al., 1997). This pocket is a critical structural element in the HIV-1 entry mechanism, serving as the essential docking site for the C-terminal heptad repeat (CHR) during the formation of the post-fusion six-helix bundle (6HB) (Root et al., 2001). The assembly of the 6HB brings the viral and host cell membranes into close proximity, facilitating the membrane fusion required for viral RNA delivery (Eckert & Kim, 2001). Due to its vital role and high sequence conservation, the pocket is a primary target for fusion inhibitors designed to block viral infection (Liu et al., 2007). Therapeutic agents such as the peptides C34 and T-1249, as well as various experimental small molecules like ADS-J1, target this pocket to competitively inhibit the NHR-CHR interaction (He et al., 2008). While the first-generation inhibitor Enfuvirtide targets the NHR region, it does not bind directly to this pocket, making pocket-specific inhibitors a key focus for overcoming Enfuvirtide resistance (Eggink et al., 2011). Resistance to pocket-targeting drugs typically involves mutations within the NHR or CHR regions that reduce binding affinity while maintaining fusion competence (Wei et al., 2002). Ongoing research continues to explore this site for the development of long-acting and orally bioavailable entry inhibitors (Xu et al., 2019).

Other names
gp41 hydrophobic pocketNHR pocketgp41 N-terminal heptad repeat pocketgp41 N-trimer cavitygp41 hydrophobic groove
02

Mechanism of action

Fusion inhibition by competitive binding to the NHR pocket, preventing six-helix bundle (6HB) formation and viral-host membrane fusion.

03

Biological functions

Viral entryMembrane fusionSix-helix bundle (6HB) formation
04

Disease associations

Infection
05

Safety considerations

Emergence of drug-resistant mutations in the gp41 NHR/CHR regionsInjection site reactions for peptide-based inhibitorsPotential for low oral bioavailability of small-molecule candidates
06

Interacting drugs

C34

4 more in the full profile.

07

Biomarkers

HIV-1 viral load (RNA)CD4+ T-lymphocyte count

Beyond the preview

Go deeper on Human immunodeficiency virus type 1 glycoprotein 41 N-terminal heptad repeat trimer pocket (gp41 N-trimer pocket).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human immunodeficiency virus type 1 glycoprotein 41 N-terminal heptad repeat trimer pocket (gp41 N-trimer pocket).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call